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1. Introduction 
Aortic aneurysms and aortic dissections account for ~16,000 deaths in the United States 
annually (Kuivaniemi, et al., 2008). Recent evidence suggests that enhanced vascular 
inflammation underlies the progression of both abdominal aortic aneurysms and thoracic 
aortic aneurysms (Guo, et al., 2006a). Common pathologic features of vascular inflammation 
and aneurysmal disease include recruitment and activation of immune cells to the vessel 
wall, myofibroblast differentiation and extracellular matrix (ECM) remodeling. Recent 
preclinical work has implicated divergent signaling pathways downstream of the 
vasopressor angiotensin II (Ang II) peptide in controlling these activities.  This work has 
elucidated two important paracrine signaling networks, one mediated by the NF-κB-IL-6 
pathway controlling monocyte activation, and the second mediated by the TGF-β-Smad2 
pathway controlling myofibroblast differentiation and T lymphocyte differentiation.  
Antagonism of Ang II signaling is being evaluated in the clinical management of patients 
with familial thoracic aneurysms. In this chapter, we will review the multifaceted role of 
Ang II in vascular inflammation in aortic aneurysmal disease. 
1.1 Types of aortic aneurysms 
Aortic aneurysms are primarily classified based on anatomic locations (Kuivaniemi, et al., 
2008). Abdominal aortic aneurysms (AAA) primarily develop in the infrarenal segment of the 
abdominal aorta in humans or suprarenal aorta in rodent models. It predominantly affects 
elderly males, and is associated with hypertension, vascular inflammation and/or 
atherosclerosis (Guo, et al., 2006a). Initial pathological events in AAA involve recruitment and 
infiltration of leukocytes into the aortic adventitia and media, which are associated with the 
production of inflammatory cytokines, chemokine, and reactive oxygen species (ROS). 
Expression of macrophage activating cytokines is increased both systemically and locally in 
AAA. Importantly, as a major source of ECM-degrading matrix metalloproteinases (MMPs), 
recruited activated macrophages promote structural remodeling by degrading elastin and 
collagen in the vessel wall (Longo, et al., 2002). Moreover, in expanding aneurysmal tissues, 
increased infiltration of inflammatory cells may amplify MMP production by resident vascular 
cells (Pearce and Koch, 1996), facilitating aortic inflammation and structural remodeling.  
In contrast, thoracic aortic aneurysms (TAA) are etiologically separable from AAA due to 
their strong genetic influence affecting areas including the ascending aorta, aortic arch, 
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and/or descending aorta. Common genetic disorders associated with TAAs include 
Marfan’s Syndrome and Loeys-Dietz syndrome. Recent studies have also identified an 
inflammatory component in the etiology of TAA (Ejiri, et al., 2003). In TAA in patients 
undergoing surgical repair, enhanced expression of cytokines, such as interleukin-6 (IL-6) 
and interferon-Ǆ (IFN-Ǆ), as well as enhanced NADPH oxidase and reactive oxygen species 
(ROS) tone are found in aortic tissues. These events are spatially correlated with increased 
monocyte/macrophage accumulation and enhanced MMP production. 
1.2 Cells and molecules implicated in inflammation in aortic aneurysms 
The vascular inflammatory response involves complex interactions between recruited 
inflammatory cells (lymphocytes, monocytes, macrophages, neutrophils), vascular resident 
cells [endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and adventitial 
fibroblasts] and the ECM. The ensuing inflammatory response increases expression of 
adhesion molecules, growth factors, cytokines and chemokines, that facilitates recruitment 
and local activation of inflammatory cells and matrix remodeling. Additionally, immune 
cells (macrophages, mast cells, B- and T- lymphocytes, neutrophils, along with VSMCs and 
adventitial fibroblasts) produce cytokines and enzymes, promoting an inflammatory 
reaction, extracellular matrix degradation, and neovascularization (Table 1).  
Recruited CD68-expressing macrophages are found in both the adventitia and intima of 
aneurysms. They are attracted to the aortic wall by elastin degradation products, CC 
chemokines [e.g. monocyte chemotactic protein (MCP-1), RANTES, etc] and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Rizas, et al., 2009). MCP-1 produced by 
VSMCs and fibroblasts (Tilson, et al., 2000) induces monocyte chemotaxis by binding to CC-
chemokine receptor 2 (CCR2). MCP-1 is an important mediator in early pathogenesis of 
aortic aneurysms because CCR2 deficiency prevents aneurysm formation in various mouse 
models (Daugherty, et al., 2010; Tieu, et al., 2009). Additionally, macrophages express 5-
lipooxygenase (5-LO), which produces macrophage inflammatory protein 1ǂ (MIP-1ǂ) to 
recruit T-cells in a paracrine fashion. Locally infiltrated T-cells then magnify the 
inflammatory cascade by secreting various CC and CXC chemokines, attracting other 
inflammatory cells to the aneurysmal tissue (Zhao, et al., 2004).  
CD3+ T-cells are abundant immunomodulatory and pro-inflammatory cells recruited to 
aneurysmal tissues, accounting for ~50% of local hematopoietic cells (Kuivaniemi, et al., 
2008). Most T-cell subtypes have been identified, including helper T-cells (Th cells), 
cytotoxic T-cells and natural killer T-cells (NKT) (Kuivaniemi, et al., 2008). Recent studies to 
identify Th cell subtypes, which are predominant in aneurysms, reported controversial 
results. Some suggested Th2 was predominant, while other studies suggested Th1 (Galle, et 
al., 2005; Schonbeck, et al., 2002).  
Aortic resident cells also potentiate inflammation via interactions with recruited immune 
cells. Adventitial fibroblasts produce cytokines and chemokines such as IL-6, MCP-1, VEGF, 
and TNF (Tilson, et al., 2000), contributing to leukocytic chemotaxis and activation. Work 
from our laboratory has found that Ang II stimulates aortic adventitial fibroblasts to recruit 
monocytes via fibroblast-derived MCP-1, and that the recruited monocytes further promote 
fibroblast proliferation, adventitial thickening, and additional cytokine production. This 
fibroblast-monocyte amplification loop may critically mediate adventitial inflammation 
(Tieu, et al., 2010; Tieu, et al., 2009). Upon stimulation with TGF-ǃ, fibroblasts differentiate 
into α-smooth muscle cell actin-expressing myofibroblasts (Desmouliere, et al., 1993).  
Myofibroblasts play a role in wound healing and fibrosis, and are associated with 
development of aneurysmal disease (Sakata, et al., 2007). 
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Cells Molecules Roles in Aortic Aneurysms 
Fibroblasts MMP-1 Collagen degradation
 MMP-2 Elastin and collagen degradation 
 VEGF Angiogenesis
 MCP-1 Monocyte chemotaxis
 
VSMCs MMP-2 Elastin and collagen degradation 
 MMP-13 Collagen degradation
 MT1-MMP 
Elastin and collagen degradation;  
ProMMP-2 activation; facilitate macrophage migration 
 MCP-1 Monocyte chemotaxis
 IL-6 
Macrophage differentiation; 
MCP-1 induction; systemic acute-phase response 
 
Macrophages MMP-3 Elastin and collagen degradation; VEGF activation 
 MMP-9 
Elastin and collagen degradation;  
dominant gelatinase in late pathogenesis;  
TGF-ǃ, VEGF activation; macrophage migration 
 MMP-12 Elastin and collagen degradation 
 MT1-MMP 
Elastin and collagen degradation;  
ProMMP-2 activation; facilitate macrophage migration 
 Cathepsins ECM degradation; angiogenesis 
 MIP-1ǂ T-cell chemotaxis
 IL-8 Neutrophil chemotaxis
 LTD4 MIP-1ǂ induction
 TGF-ǃ Angiogenesis; MMP induction; 
Th17 differntiation; myofibroblast differntiation 
 IL-6 
Macrophage differentiation; 
MCP-1 induction; systemic inflammatory responses 
 
Mast cells Chymases ProMMP activation; VSMC apoptosis; Ang II induction 
 Tryptases ProMMP activation
 LTD4 MIP-1ǂ induction
 
Netrophils MMP-8 Collagen degradation
 MMP-9 
Elastin and collagen degradation; 
TGF-ǃ, VEGF activation; macrophage migration 
 Cathespins ECM degradation; angiogenesis 
 Netrophil elastase Elastin degradation
 
NKT cells IFN-Ǆ Th1 differentiation; macrophage activation 
 IL-4 Th2 differentiation; humoral immunity 
 
Th Cells IFN-Ǆ Th1 differentiation; macrophage activation 
 IL-4 Th2 differentiation; humoral immunity 
 IL-17 Macrophage chemotaxis
Table 1. Major cell types and secreted molecules involved in vascular inflammatory 
response in aortic aneurysms. 
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Among the different enzymes secreted by immune and stromal cells, MMP-2, MMP-9, 
MMP-12, cathepsins, and neutrophil elastase cause ECM degeneration (Table 1). Chymase 
causes smooth muscle cell apoptosis, and MMP-3, MMP-8, and MMP-13 cause adventitial 
collagen degradation, promoting abdominal aortic aneurysm rupture.  
Cytokines and chemokines such as IL-8, MIP-1ǂ, and MCP-1 facilitate recruitment and 
proliferation of inflammatory cells (Table 1). Cytokines include TNF, interleukins, 
interferons, colony stimulating factors, and transforming growth factors, etc. They are 
produced by diverse cell types including macrophages, T-cells and monocytes, VSMCs and 
fibroblasts. Circulating cytokines interact with specific receptors on various cell types to 
activate JAK-STAT, NF-κB, and Smad signaling pathways, regulating expression of various 
genes controlling inflammatory response involving cell adhesion, permeability and 
apoptosis. Cytokine signaling is also known to increase mitochondrial ROS production, 
induce integrins to facilitate cellular adhesion and activate MMPs to modify ECM 
composition. Further, increased local cytokine expression is implicated in aortic aneurysms. 
Vascular inflammation is an ordered process producing recruitment of activated leukocyte 
subtypes into the vessel wall, initiating complex interaction with vascular residential cells 
and ECM. This process is initiated and amplified by local secretion of adhesion molecules, 
chemotactic factors and cytokines, whose inducible expression are signaled by vascular 
injury and modulated by vasoactive peptides (Ang II), CD40 ligands, oxidized cholesterol, 
and advanced glycation end products.  Of these, the effects of Ang II have been implicated 
in vascular inflammation and have emerged as an important clinical target for the treatment 
of human aneurysms associated with Marfan’s disease. 
2. Ang II-induced vascular inflammation 
Angiotensin II (Ang II) is the major effector peptide of the renin-angiotensin system.  In 
addition to its potent vasoconstrictor actions, Ang II exert pro-inflammatory activity in the 
vascular wall, inducing production of inflammatory cytokines, adhesion molecules, and 
formation of ROS, resulting in macrophage accumulation, myofibroblast differentiation, and 
localized aortic dilation  followed by dissections (Ejiri, et al., 2003).  
Ang II is a potent inducer of vascular inflammation producing acute thoracic and suprarenal 
aortic aneurysms and dissections in many mouse models (Daugherty, et al., 2010; Tieu, et al., 
2009). Chronic subcutaneous infusion of Ang II peptide into atherosclerosis-prone 
hyperlipidemic apolipoprotein E-deficient (ApoE-/-) or LDL receptor (LDLR-/-) deficient 
mice produces thoracic and suprarenal aneurysms (Reiner, 2007) . Also in aged C57BL/6J 
mice, Ang II produces both suprarenal and ascending thoracic aneurysms and dissections, 
albeit at a lower frequency than in the presence of hyperlipidemia (Tieu, et al., 2009). 
Moreover, Ang II type I receptor and ACE polymorphisms are associated with AAA in humans 
(Jones, et al., 2008), suggesting that Ang II is tightly associated with aneurysmal diseases. The 
mouse models of acute Ang II infusion showed significant vascular inflammatory responses in 
aneurysmal tissues, including enhanced aortic cytokine/chemokine production, early 
macrophage recruitment, elastin degeneration, and intramural hematoma formation.  
Ang II stimulates inflammatory chemokine expression and ROS production in EC and VSCMs, 
events implicated in the pathogenesis of aortic aneurysms (Ejiri, et al., 2003; Longo, et al., 
2002). In ECs, Ang II up-regulates expression of the leukocyte adhesion molecules vascular cell 
adhesion molecule (VCAM-1), intercellular adhesion molecule (ICAM-1), and selectins (Pueyo, 
et al., 2000), facilitating monocyte adhesion and recruitment into the vascular wall. Once 
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recruited, monocytes produce MMPs that mediate aortic wall remodeling in aneurysmal 
expansion, and migrate towards gradients of chemotactic cytokines (e.g. MCP-1, KC/Groǃ, 
MIP-1ǂ, etc). The actions of Ang II regulate many steps in these processes, inducing expression 
of chemokines MCP-1, KC/Groǃ, and the cytokine IL-6 (Chen, et al., 2001; Han, et al., 1999). In 
VSMCs, Ang II is a potent inducer of cytokine and chemokine expression, including MCP-1 
and IL-6. These molecules, in turn, cause more immune cell infiltration, further amplifying the 
inflammatory tone contributing to aneurysmal expansion. 
The ability of Ang II to potently induce vascular inflammation involves the activation of two 
divergent signaling pathways important in the vascular stress response, the first being the 
nuclear factor-κB (NF-κB)-IL-6 signaling pathway, and the second, the transforming growth 
factor (TGF)-ǃ-Smad pathway (Figure 1). 
 
 
Fig. 1. Ang II-induced signaling pathways involved in vascular inflammatory events 
implicated in aortic aneurysms. The actions of Ang II involve cells directly responding to its 
actions schematically diagrammed as generators and downstream affected cells 
(responders) producing vascular inflammation and remodeling  
3. The NF-κB-IL-6 pathway in Ang II-induced aortic aneurysms 
A number of recent studies have demonstrated that NF-κB transcription factors play a 
central role in controlling the process of vascular inflammation. Responsive to vasoactive 
peptides such as Ang II, oxidized LDL, activated CD40 receptor, monocyte released 
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cytokines, or advanced glycation end-products, activated NF-κB is known to control 
leucocyte adherence and chemotaxis, key steps in the process of vascular inflammation. 
Recently, an additional role for NF-κB in controlling monocyte activation via the IL-6 
pathway has also been discovered. Here, locally secreted IL-6 activates vascular monocytes 
and induces cellular protection from ROS-induced stress via signaling through the 
downstream effector signal transducer and activator of transcription 3 (STAT3). In this way, 
the NF-κB –IL-6 signaling pathway plays multiple roles in initiating and sustaining vascular 
inflammation. 
3.1 Mechanism of NF-κB activation by Ang II in VSMCs 
Ang II initiates intracellular signaling by binding to two types of heterotrimeric guanosine 
(G) -protein coupled 7-transmembrane receptors, termed the type I (AT-1) and type II (AT-2) 
Ang II receptors (Griendling, et al., 1997). AT-1 is the major receptor normally expressed on 
ECs, VSMCs, cardiomyocytes and monocytes (Murphy, et al., 1991). These receptors are 
activated by Ang II ligand binding in a G protein-dependent manner. The activation of G 
protein-dependent signals activates phospholipase Cǃ to increase intracellular inositol 
trisphosphate and diacylglycerol, leading to increase in calcium and activation of protein 
kinase C (PKC) isoforms.  
In vascular cells, although Ang II activates multiple second messenger pathways including 
phospholipase D, PKC, and the mitogen activated protein kinase/erk kinase (MEK/ERK) 
pathways, recent attention has been drawn to the Rho family of GTPases (Griendling, et al., 
1997). The Rho family is a group of 20-21 kDa GTPases including RhoA, B, C, D and E; Rac1 
and 2; Cdc42Hs and TC10. The three Rho family members primarily expressed in vascular 
tissues in humans include RhoA, Rac1, and Cdc42Hs. Under unstimulated conditions, the 
Rho proteins are cytosolic, bound to GDP and guanine nucleotide dissociation inhibitors 
(Van Aelst and D'Souza-Schorey, 1997). In response to Ang II stimulation, the ligand 
binding of the G-protein-coupled AT-1 activates guanine nucleotide exchange factors 
(GEFs), which in turn catalyze GDP-GTP exchange and activates the Rho GTPases (Figure 
1). Activated RhoA affects ROS production and controls smooth muscle cell contractility by 
phosphorylating myosin light chain kinase (MLCK), enhancing DNA synthesis, inducing 
VSMC migration, stimulating cardiovascular fibrosis (Kobayashi, et al., 2002), and inducing 
hemostatic and inflammatory proteins (Kobayashi, et al., 2002). 
NF-κB is a ubiquitously-expressed, highly inducible transcription factor complex 
composed of both latent cytoplasmic and activated nuclear components. One major 
activation NF-κB pathway that we and others have defined is referred to as the 
“canonical” pathway, a pathway that controls nuclear targeting of latent cytoplasmic Rel 
ANF-κB1 heterodimeric complexes. Rel ANF-κB1 is retained in a cytoplasmic location 
by association with the IκBǂ inhibitor (Beg and Baldwin, 1993). Stimuli inducing the 
canonical NF-κB pathway activate the IKK kinase complex, resulting in IκBǂ 
phosphorylation at specific N-terminal serine residues, ultimately targeting it for 
proteosomal degradation (Ghosh and Baltimore, 1990). As a result, sequestered Rel 
ANF-κB1 complexes are then released to enter the nucleus. Nuclear translocated Rel 
ANF-κB1 then binds to specific regulatory sequences in cytokine and acute phase 
reactant promoters, activating their transcription. 
Although initially the Ang II signaling pathway was thought to induce the canonical NF-κB 
activation pathway in VSMCs, detailed studies have shown that Ang II induces cell type-
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dependent activation of NF-κB pathways (Brasier, 2010). In non-vascular cells such as 
hepatocytes, PKC activation leads to cleavage of the IKK inhibitory TNFAIP3/A20 molecule 
and degradation of IkBǂ through the mechanisms as in canonical signaling induced by 
TNFǂ, resulting in activation of NF-κB translocation. In VSMCs, on the other hand, the Ang 
II-induced pathway is quite distinct from other cell types. A novel activation pathway 
independent of the well-recognized canonical pathway described above was identified by us 
and schematically diagrammed in Figure 1. In VSMCs, inactive NF-κB isoforms could be 
identified in unstimulated cells, and no significant changes in NF-κB abundance was 
observed in response to Ang II stimulation. Of importance, we found that Ang II stimulation 
rapidly induces phosphorylation of RelA at serine residue 536 in its COOH-terminal 
transactivating domain. Interestingly, we also found that phospho-Ser-536 RelA formation 
was blocked by RhoA inhibition, suggesting that Ser-536 phosphorylation was mediated 
upstream by RhoA. In addition, RhoA inhibition also blocked Ang II-induced IL-6 
expression, indicating that Ang II-inducible phospho-Ser-536 RelA was required for IL-6 
activation (Cui, et al., 2006).  
Our studies in Ang II-stimulated VSMCs further showed that total RelA binding did not 
change on the native IL-6 promoter in response to Ang II, but fractional binding of 
phospho-Ser-536 RelA to the IL-6 promoter was increased (Choudhary, et al., 2007). These 
studies showed that Ang II induces NF-κB /RelA activation in VSMCs by increasing the 
relative abundance of phospho-Ser-536 RelA in the nucleoplasmic pool. We also 
confirmed Ang II-induced enhanced phospho-Ser-536 RelA formation in rat aortas treated 
with Ang II, establishing relevance to vascular signaling in vivo (Choudhary, et al., 2007; 
Cui, et al., 2006).  
Our group further showed that Ang II-induced RelA Ser-536 phosphorylation is mediated 
by NF-κB-inducing kinase (NIK), the major regulated step controlling non-canonical NF-κB 
signaling. NIK inhibition prevented Ang II-induced Ser-536 phosphorylation and NF-κB-
dependent transcription (Choudhary, et al., 2007), indicating that it is essential for RelA 
activation. We also found that NIK induced the activity of the RelA transactivation domain-
1 and -2 in constitutively nuclear RelA proteins and that RelA formed an inducible nuclear 
complex with NIK in response to Ang II stimulation. The function and mechanism of this 
NIK·RelA complex in Ang II-induced vascular inflammation still requires further 
investigation.  
Taken together, this data indicate that in VSMCs, where inactive NF-κB is constitutively 
nuclear, Ang II induces NF-κB -dependent transcription through an alternative pathway, 
being largely independent of IκB proteolysis, but mediated by the small GTPases 
Rac/RhoA, required for NIK·RelA complex formation and inducible phospho-Ser-536 RelA 
phosphorylation. 
3.2 Vascular inflammatory actions of Ang II-induced NF-κB signaling 
Ang II-induced NF-κB activation plays a central role in the development of aneurysms 
through regulation of gene expression of inflammatory molecules whose function broadly in 
the cascade of leukocyte recruitment and monocyte chemotaxis. These targets include pro-
inflammatory cytokines (e.g. interleukins, etc.), chemokines (e.g. MCP-1, GM-CSF, etc.), 
adhesion molecules (e.g. E-selectin, ICAM-1, VCAM-1, etc.), and ECM-degrading MMPs. 
A major target of Ang II-induced NF-κB activation is to activate expression of IL-6 by 
adventitial fibroblasts, recruited monocytes and VSMCs. Ang II induces rapid activation of 
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IL-6 transcription and translation (Han, et al., 1999). The transcriptional activation of IL-6 
expression is mediated by NF-κB binding to its high affinity binding site in this proximal 
promoter of the IL-6 gene. This site is required for Ang II inducible expression since Ang II 
inducible activity is completely abolished by a promoter containing a point mutation that 
does not bind NF-κB (Han, et al., 1999). Together, these data suggest that NF-κB 
transcription factor is required for inducible expression of the IL-6 by Ang II.  
IL-6 is a 26 kDa glycosylated cytokine that acts in a paracrine manner to signal through two 
distinct mechanisms, termed the classical initiated by membrane receptor binding, and the 
trans-signaling pathway mediated by soluble IL-6 Rǂ (Hou, et al., 2008). Classical IL-6 
signaling is mediated via ligand binding to the IL-6Rǂ receptor on the cell membrane. The 
IL-6 trans-signaling pathway, on the other hand, involves circulating IL-6·IL-6Rǂ 
engagement with gp130 expressed on cells, enabling activation of the IL-6 signaling 
pathway in cells lacking IL-6Rǂ. In trans-signaling, proteolysis and/or alternative splicing 
lead to the generation of soluble IL-6 receptors (sIL-6R), which binds IL-6. The IL-6/sIL-6R 
complex can stimulate cells that only express gp130 but no IL-6R.  
In IL-6-initiated classical signaling, the IL-6IL-6Rǂ complex causes oligomerization with 
the ubiquitously expressed transmembrane gp130 ǃ-subunit, inducing gp130 
homodimerization, and subsequent formation of a hexameric IL-6IL-Rǂgp130 complex 
(Boulanger, et al., 2003). This induces conformational changes of gp130, that trigger trans-
autophosphorylation and activation of Janus tyrosine kinase JAK1, a specific Janus kinase 
mediating IL-6 signaling. JAK1 in turn induces tyrosine phosphorylation and activation of 
STAT isoforms STAT1 and STAT3 (Figure 1). As transcription factors, they then form homo- 
and heterodimers with each other, translocate to the nucleus, bind specific DNA sequences 
and enhance transcription of target genes via interactions with co-factors and co-activators 
such as p300/CREB-binding protein (CBP) and Positive Transcription Elongation Factor 
(PTEF-b) (Hou, et al., 2008).  
IL-6 plays a major role in inducing systemic responses to the presence of vascular 
inflammation through the hepatic acute-phase response (Brasier, et al., 2002). IL-6 has 
diverse actions in multiple cell types of cardiovascular importance, including ECs, 
monocytes, platelets, hepatocytes and adipocytes. In the vessel, IL-6 promotes Ang II-
induced ROS production because IL-6 deficiency protects against Ang II-induced 
endothelial dysfunction (Schrader, et al., 2007).  
Importantly, a major action of IL-6 is to promote monocyte-to-macrophage differentiation, 
thus contributing to vascular inflammation. IL-6 stimulation increases esterase and 
phagocytic activities and enhances surface expression of Fc receptors, macrophage-colony 
stimulating factor (M-CSF) receptors, and the mature macrophage marker F4/80. 
Additionally, IL-6 induces expression of genes important for macrophage differentiation 
such as c-Jun, jun B, jun D, interferon-regulatory factor 1 (IRF1), JAK3, Egr-1 (Hou, et al., 
2008). Moreover, IL-6 up-regulates MCP-1 expression (Biswas, et al., 1998; Tieu, et al., 2009) 
by vascular monocytic cells. MCP-1/CCR2 interactions are important in monocyte 
recruitment in the development of aneurysms (Boring, et al., 1998; Tieu, et al., 2009). Also, 
cell-cell interaction of monocytes and fibroblasts in cocultures induces IL-6 expression and 
macrophage activation, suggesting a role of IL-6 in monocyte-to-macrophage differentiation 
(Chomarat, et al., 2000; Tieu, et al., 2010). Recent studies demonstrated that IL-6-induced 
downstream gp130-JAK/STAT signaling pathway activation is also important for 
differentiation of monocytes (Hou, et al., 2008).  
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Recent studies indicate that enhanced IL-6 signaling is associated with vascular 
inflammation and aneurysm formation. IL-6 is elevated systemically and locally in patients 
and experimental models of aortic aneurysmal disease. IL-6 deficiency decreases aortic 
chemokine secretion and macrophage recruitment, and prevents aortic aneurysms and 
dissections in Ang II-infused mice (Tieu, et al., 2009). Conversely, in wild type mice, Ang II 
infusion potently induces IL-6 expression in the aorta, making IL-6 the most abundantly 
secreted cytokine that has yet been detected. IL-6 is predominantly expressed by fibroblasts 
and activated macrophages in the adventitia, with lesser amounts in the media and intimal 
layers (Recinos, et al., 2007). IL-6 signaling pathway was locally activated in Ang II-induced 
aortic aneurysms (Tieu, et al., 2009),where its action promotes monocytic activation and 
adventitial macrophage accumulation via a chemokine MCP-1-CCR2-based mechanism 
(Ishibashi, et al., 2004; Tieu, et al., 2009). These activated macrophages in the vessel wall 
produce pro-inflammatory cytokines, chemokines, ROS and MMPs, further facilitating local 
inflammation and remodeling. 
4. The TGF-β-Smad pathway in Ang II signaling 
The second pathway initiated by Ang II involves TGF-ǃ receptor signaling pathway 
important in myofibroblast transition and vascular ECM remodeling, characteristic of 
aneurysmal disease. This cross-talk pathway is mediated by the effect of Ang II to 
upregulate TGF-ǃ. TGF-ǃ, in turn, induces the proliferation of adventitial fibroblasts and 
their phenotypic transition to myofibroblasts, that further promotes vascular remodeling 
with their enhanced mobility and secretory abilities. Additionally, Ang II-induced ECM 
decomposition and remodeling lead to monocytic chemotaxis and the release of latent TGF-
ǃ. TGF-ǃ activation induces aortic Smad signaling, which further contributes to MMP 
production and macrophage recruitment. Finally, in conjunction with IL-6, TGF-ǃ also 
modulates Th lymphocyte subsets by promoting Th17 cell differentiation via activation of 
Smad and STAT signaling.   
4.1 TGF-β-Smad signaling mechanisms 
TGF-ǃ activates cells by binding to one of 7 type I TGF-ǃ receptors (TGF-ǃRI) or 5 type II 
TGF-ǃ receptors (TGF-ǃRII). In the cell, TGF-ǃ signals through both Smad-dependent (Jones, 
et al., 2008) and Smad-independent (p38 MAP kinase-mediated) pathways (Funaba, et al., 
2006). In the classic Smad-dependent pathway, ligand binding of TGF-ǃ dimers leads to 
autophosphorylation and activation of a TGF-ǃRII homodimer, which in turn recruits and 
phosphorylates a TGF-ǃRI homodimer (Figure 1). TGF-ǃRI phosphorylates the appropriate 
receptor-activated Smad (R-Smad) (Jones, et al., 2008). Depending on the TGF-ǃRI that 
phosphorylates and activates them, there are 5 R-Smads in 2 groups (Smads 1, 5, 8; and 
Smads 2, 3). Once phosphorylated, R-Smad dissociates from TGF-ǃRI to form a complex 
with Smad4 (co-Smad), that translocates to the nucleus and regulates gene expression by 
binding to Smad binding elements. The signaling can also be regulated by inhibitory Smads 
(I-Smads), which attenuate the TGF-ǃ response (Jones, et al., 2008). 
4.2 Ang II and TGF-β interaction in TAAs 
Recent studies have extensively focused on the role of TGF-ǃ in the development of different 
forms of aortic aneurysms.  Studies on TAAs caused by Marfan or Loeys-Dietz syndromes 
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suggested a critical pathogenic role for increased TGF-ǃ signaling in promoting abnormal 
vessel remodeling, dilatation, and aneurysmal expansion. Enhanced TGF-ǃ signaling was 
implicated in aortic dilatation and aneurysm formation in Loeys-Dietz syndrome caused by 
mutations in the genes encoding TGF-ǃRI and TGF-ǃRII (Loeys, et al., 2005). In Marfan 
syndrome caused by mutations in the fibrillin-1 gene, bioavailability of TGF-ǃ1is 
dysregulated (Chaudhry, et al., 2007), which contributes to the pathogenesis of TAAs (Dietz, 
et al., 2005; Neptune, et al., 2003). Normally, fibrillin-1 in the extracellular matrix regulates 
TGF-ǃ activation by sequestering it in a complex with latent TGF-binding proteins (LTBPs). 
LTBPs associate matrix microfibrils with latency-associated peptide (LAP), regulating TGF-ǃ 
matrix association and activation (Figure 1). Recent studies of fibrillin-1 deficient (Fbn1-/-) 
mice have shown that several cardiovascular pathologies are caused by abnormal up-
regulation of TGF-ǃ signaling. Enhanced formation of activated TGF-ǃ and phospho-Smad2, 
a downstream signaling protein activated by TGF-ǃ, are detected in cardiovascular tissues. 
Importantly, neutralizing antibodies to TGF-ǃ administered to Fbn1-/- mice reduce 
pathological abnormalities, suggesting a critical role of TGF-ǃ signaling in the development 
and progression of TAA (Neptune, et al., 2003).  
Interestingly, enhanced Ang II signaling, which is a potent inducer of cytokines and 
chemokines, has also been implicated in Marfan syndrome. Aortic Ang II concentration is 
increased in aortas of mice with fibrillin mutations (Nagashima, et al., 2001). Also, the Ang II 
type I receptor antagonist, Losartan, prevents aortic aneurysm formation in patients with 
Marfan syndrome (Habashi, et al., 2006). The ACE inhibitor perindopril reduced aortic 
diameter in Marfan syndrome patients and significantly reduced TGF-ǃ levels and plasma 
levels of MMP-2 and MMP-3. In addition, Ang II enhances TGF-ǃ actions by activating 
Smad pathway in a TGF-ǃ-independent manner (Carvajal, et al., 2008). It also induces the 
production of a potent activator of TGF-ǃ, thrombospondin-1 (Habashi, et al., 2006). These 
data suggest that Ang II activates TGF-ǃ signaling, contributing to aneurysm formation. 
Ang II may activate TGF-ǃ signaling by regulating its transcription and/or its activation 
from the latent form (Habashi, et al., 2006). Previous studies have shown that in renal 
disease, Ang II regulates TGF-ǃ signaling activation by activating tumor necrosis factor 
TNF-ǂ-converting enzyme (TACE), which through the cleavage of vasorin, controls TGF-ǃ-
mediated epithelial-to-mesenchymal transition (Shah and Catt, 2006).  
In a mouse model with fibrillin deficiency (mgR), an inflammatory-fibroproliferative 
response has been described in aneurysm formation. Homozygous mgR mice die between 3 
and 6 months of age of dissecting TAAs, and adventitial inflammation may accelerate 
pathogenesis by stimulating unregulated degradation of elastic matrix. In this mouse model, 
enhanced monocyte/macrophage infiltration is also pronounced at late stages of disease 
progression (Pereira, et al., 1999). Additionally, aortas from these mice secrete a GxxPG-
containing fibrillin-1 fragment that is able to induce macrophage chemotaxis (Guo, et al., 
2006b). Together, these findings suggest that inflammation is important in extracellular 
matrix degradation associated with fibrillin deficiency-induced TAAs. Two recent reports 
by the Dietz's group of Johns Hopkins University suggested that the effects of Ang II on 
aneurysm progression in MFS was mediated through a noncanonical TGF-beta signaling 
pathway involving extracellular signal-regulated kinase (ERK). It was reported that ERK 
activation contributed to aortic aneurysm progression in MFS (Holm, et al., 20111). Using a 
mouse model haplo-insufficient for Fbn-1 (Fbn1C1039G/+), this group found that ERK1/2 was 
activated and that ERK inhibition, but not Smad4 deficiency, eliminated aneurysm 
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development in MFS. It also was reported that AT1 receptor blocker losartan abrogated 
aneurysm progression by inhibiting TGF-beta-mediated ERK activation through AT2 
(Habashi, et al., 2011). 
Increased expression and activation of TGF-ǃ are found in Ang II-induced AAAs. Preliminary 
studies from our group also demonstrated that Ang II induced Smad2/3 phosphorylation in 
mouse aortas. However, the precise role of TGF-ǃ activity in inflammation in aneurysms 
remains contradictory. One study reported that TGF-ǃ neutralizing antibodies afforded 
significant protection from Ang II-induced inflammatory aneurysms after Cxcl10 targeting 
(King, et al., 2009), while other studies showed that TGF-ǃ played a protective role in AAA 
formation and TGF-ǃ neutralization increased Ang II-induced aneurysm and monocyte 
invasiveness in C57BL/6 mice (Dai, et al., 2005; Wang, et al., 2010). Controversial results 
indicating the protective role of TGF-ǃ in AAA formation may be explained by the 
concentration-dependent bipolar actions of TGF-ǃ. With a higher dose of Ang II infusion in 
aged C57BL/6 mice (Tieu, et al., 2009), our preliminary studies showed that TGF-ǃ 
neutralization decreased incidence of Ang II-induced aneurysm and adventitial thickening. 
Emerging evidence highlights the complex and context-dependent biphasic effects of TGF-ǃ in 
the pathogenesis of aneurysm (Jones, et al., 2008), that can be partially explained by interaction 
with different receptors when TGF-ǃ concentration changes (Goumans, et al., 2002). It may 
also be important to consider the variable roles of TGF-ǃ during the dynamic transition from 
predisposition to terminal events. Thus, the detailed role of TGF-ǃ in inflammatory aneurysms 
may be very complex and merits further exploration. 
Also, we have recently demonstrated that co-culture of monocytes with adventitial 
fibroblasts resulted in enhanced expression of IL-6, MCP-1 and IL-6-dependent macrophage 
differentiation (Tieu, et al., 2009). It is interesting to speculate that TGF-ǃ may play a role in 
this process as a paracrine factor (Dietz, 2010). TGF-ǃ is known to induce IL-6 and MCP-1 
expression (Seong, et al., 2009; Zhang, et al., 2009), monocyte recruitment and differentiation 
and myofibroblast formation, which in turn may amplify the process through secretion of 
TGF-ǃ, MMPs, or even MCP-1 (Dagouassat, et al., 2010). 
4.3 Effects of TGF-β-Smad signaling activation in aneurysms 
TGF-ǃ has both angiogenic and antiangiogenic effects (Goumans, et al., 2002), diametric 
actions thought to be controlled by the ratio of TGF-ǃ signals via different receptors.  
Also, TGF-ǃ produces opposing effects on mast cells to inhibit maturation or induce 
apoptosis, depending on their developmental stage and the TGF-ǃ concentration (Rizas, et 
al., 2009).  
Additionally, TGF-ǃ controls both ECM synthesis and degradation (Jones, et al., 2008). TGF-ǃ 
promotes ECM degradation by inducing MMP-2 and MMP-9 production (Kim, et al., 2007). 
On the other hand, TGF-ǃ stimulates both fibroblasts (Varga and Jimenez, 1986) and 
myofibroblasts (Mishra, et al., 2007) to synthesize collagen I, that provides load-bearing 
characteristics, and collagen III, that provides tensile properties to the aortic wall (van Keulen, 
et al., 2000). TGF-ǃ also induces ǂ-smooth muscle actin expression  in fibroblasts and promotes 
myofibroblast transdifferentiation (Vaughan, et al., 2000). The expression of ǂ-smooth muscle 
actin was found to be significantly increased in adventitial fibroblasts of inflammatory aortic 
aneurysms, suggesting inflammatory remodeling in aneurysmal disease may be partly 
mediated by the proliferation of adventitial myofibroblasts (Sakata, et al., 2007).  
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It is also noteworthy that TGF-ǃ engages in adaptive immunity by promoting the 
differentiation of naïve CD4+ T helper cells (Th0) to T helper 17 (Th17) cells via activation of 
Smad and STAT signaling, depending on the coinstantaneous presence of IL-6 or IL-21 
(Reiner, 2007). TGF-ǃ activation is critical and required for differentiation of Th17 cells 
(Melton, et al., 2010). It activates signature transcription factor RORǄT (retinoic-acid receptor 
related orphan receptor gt) and cytokine IL-17 expression (Oukka, 2008). IL-17 mediates the 
production of inflammatory cytokines by stromal cells, which results in recruitment of 
leukocytes, thus creating a link between innate and adaptive immunity. Th17 cells and IL-
17A have been implicated in the pathogenesis of autoimmune and inflammatory diseases 
(Tesmer, et al., 2008), and only recently in cardiovascular disease (Cheng, et al., 2008). 
Increased circulating Th17 cells and Th17 cell infiltration into the aorta are found in Ang II-
induced hypertension, and IL-17 deficiency blunts these responses and prevents 
hypertension (Madhur, et al., 2010). Further, Th17 cells as well as IL-17 expression in 
atherosclerosis are increased, and blockade of IL-17A reduced aortic macrophage 
infiltration, cytokine secretion, and atherosclerotic plaque formation. Interestingly, IL-6 
expression is induced by IL-17 and reduced by blockade of IL-17A signaling (Smith, et al., 
2010), suggesting the proinflammatory effects of IL-6 could also be mediated by Th17 cells. 
Importantly, IL-17 and, by extension, Th17 cells, may contribute to inflammatory processes 
by promoting monocyte chemotaxis, adhersion and migration. It has recently been found 
that IL-17 mediated monocyte migration partially through MCP-1 induction (Shahrara, et 
al., 2010). IL-17A treatment of aortas from atherosclerotic mice promoted aortic CXCL1 
expression and monocyte adhesion (Smith, et al., 2010). These studies highlight an 
important proinflammatory role for T cells, especially the Th17 subset, in vascular 
inflammation. 
5. Conclusion 
Recent preclinical research has indicated that Ang II influences development and 
progression of aortic aneurysmal disease in two important ways.  First, Ang II affects the 
process of vascular inflammation by promoting macrophage accumulation, activation, local 
ROS production and aortic aneurysms in the suprarenal and thoracic aorta, followed by 
dissections through the NF-κB-IL-6 signaling pathway.  Second, Ang II promotes 
myofibroblast transition and ECM remodeling - both characteristic of aneurysmal disease - 
by a TGF-ǃ1-Smad pathway. Currently, there are still many important unresolved 
questions. For example, 1) the role of NF-κB RelA activation in the development of 
aneurysms; 2) the mechanism through which Ang II activates TGF-ǃ in the vessel wall; 3) 
the precise role of TGF-ǃ signaling in Ang II-induced aortic aneurysms; 4) the role of 
myofibroblast formation in the development of aortic remodeling and aneurysms; 5) the role 
of TGF-ǃ signaling on Th17 cell differentiation and recruitment in the development of Ang 
II-induced aneurysms; and 6) clinical relevance of TGF-ǃ neutralization in aneurysmal 
disease. Further elucidation of these issues will identify new targets for therapeutic 
intervention and biomarker development. 
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